Sleep Apnea - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Sleep Apnea - Pipeline Review, H2 2016

Sleep Apnea - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Sleep Apnea - Pipeline Review, H2 2016
Published Aug 17, 2016
60 pages — Published Aug 17, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Sleep Apnea - Pipeline Review, H2 2016, provides an overview of the Sleep Apnea pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Sleep Apnea, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sleep Apnea and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Sleep Apnea
- The report reviews pipeline therapeutics for Sleep Apnea by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Sleep Apnea therapeutics and enlists all their major and minor projects
- The report assesses Sleep Apnea therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Sleep Apnea

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Sleep Apnea
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Sleep Apnea pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-lic

  
Source:
Document ID
GMDHC8365IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables41
  List of Figures41
Introduction51
  Global Markets Direct Report Coverage51
Sleep Apnea Overview61
Therapeutics Development72
  Pipeline Products for Sleep Apnea Overview71
  Pipeline Products for Sleep Apnea Comparative Analysis81
Sleep Apnea Therapeutics under Development by Companies91
Sleep Apnea Therapeutics under Investigation by Universities/Institutes101
Sleep Apnea Pipeline Products Glance113
  Late Stage Products111
  Clinical Stage Products121
  Early Stage Products131
Sleep Apnea Products under Development by Companies141
Sleep Apnea Products under Investigation by Universities/Institutes151
Sleep Apnea Companies Involved in Therapeutics Development164
  Galleon Pharmaceuticals161
  RespireRx Pharmaceuticals Inc.171
  SK Biopharmaceuticals Co., Ltd.181
  Vivus, Inc.191
Sleep Apnea Therapeutics Assessment208
  Assessment by Monotherapy Products201
  Assessment by Combination Products211
  Assessment by Target222
  Assessment by Mechanism of Action242
  Assessment by Route of Administration261
  Assessment by Molecule Type271
Drug Profiles2818
  (phentermine + topiramate) ER Drug Profile287
  CX-1739 Drug Profile353
  dronabinol Drug Profile382
  GAL-475 Drug Profile401
  GAL-475 Backups Drug Profile411
  SKL-N05 Drug Profile423
  Small Molecule for Sleep Apnea Drug Profile451
Sleep Apnea Dormant Projects461
Sleep Apnea Discontinued Products471
Sleep Apnea Product Development Milestones4811
  Featured News &Press Releases481
    Jun 14, 2016: Jazz Pharmaceuticals Presents New Data from a Human Abuse Liability Study for JZP-110, an Investigational Treatment for Excessive Sleepiness in Patients with Narcolepsy or with Obstructive Sleep Apnea, at 30th Annual SLEEP Meeting481
    Feb 29, 2016: RespireRx Pharmaceuticals Announces Removal of FDA Clinical Hold on CX1739 and Initiation of Phase IIA Clinical Trial by March 31, 2016491
    Jun 08, 2015: Jazz Pharmaceuticals Announces First Patients Enrolled in Phase 3 Clinical Development Program Evaluating JZP-110 as a Potential Treatment of EDS Associated with Narcolepsy or with OSA491
    May 14, 2015: VIVUS Announces Scientific Presentations501
    May 04, 2015: Cortex Pharmaceuticals Announces Publication of Research Results on the Use of Ampakines CX1739 in the Treatment of Respiratory Disorders511
    May 04, 2015: Cortex Pharmaceuticals Announces Publication of Research Results on the Use of Ampakines CX1739 in the Treatment of Respiratory Disorders521
    May 15, 2014: VIVUS Announces Qsymia Presentation at the American Association of Clinical Endocrinologists521
    Jul 01, 2013: VIVUS Announces Initial Availability of Qsymia Through Certified Retail Pharmacies531
    Nov 12, 2012: Study Finds Significant Improvements In Patients With Obstructive Sleep Apnea Treated With Phentermine And Topiramate Extended-Release Capsules541
    Jan 09, 2012: VIVUS Provides Update On Regulatory Status Of Qnexa551
    Nov 03, 2011: FDA Accepts New Drug Application Filing For Qnexa551
    Apr 26, 2011: Cortex Receives US Patent For Lead AMPAKINE Molecule CX1739561
    Feb 02, 2011: Cortex s Ampakine CX1739 Improves Respiratory Parameters In Obstructive Sleep Apnea Patients561
    Jan 07, 2010: VIVUS Announces Positive Results From Phase II Study Of Qnexa In Obstructive Sleep Apnea572
Appendix592
  Methodology591
  Coverage591
  Secondary Research591
  Primary Research591
  Expert Panel Validation591
  Contact Us591
  Disclaimer601

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Sleep Apnea - Pipeline Review, H2 2016" Aug 17, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Sleep-Apnea-Pipeline-Review-H2-2016-2088-16392>
  
APA:
Global Markets Direct - Market Research. (2016). Sleep Apnea - Pipeline Review, H2 2016 Aug 17, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Sleep-Apnea-Pipeline-Review-H2-2016-2088-16392>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.